# EDGAR Filing Document

**Accession Number:** 0001674712
**File Stem:** 0001213900-25-081215
**Filing Date:** 2025-8
**Character Count:** 15824
**Document Hash:** c913f2b7642404706d77db1a096ff695
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-081215.hdr.sgml**: 20250827

**ACCESSION NUMBER**: 0001213900-25-081215

**CONFORMED SUBMISSION TYPE**: N-PX

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250827

**EFFECTIVENESS DATE**: 20250827

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Vivo Capital, LLC
- **CENTRAL INDEX KEY:** 0001674712

**ORGANIZATION NAME:**
- **EIN:** 203075737
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** N-PX
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 028-17467
- **FILM NUMBER:** 251266458

**BUSINESS ADDRESS:**
- **STREET 1:** 192 LYTTON AVENUE
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301
- **BUSINESS PHONE:** 650-688-0818

**MAIL ADDRESS:**
- **STREET 1:** 192 LYTTON AVENUE
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301

## FORM N-PX
### ANNUAL REPORT OF PROXY VOTING RECORD

## N-PX: Filer Information

**Filer CIK:** 0001674712

**Date of Report:** 06/30/2025

**Are you a Registered Management Investment Company or an Institutional Manager?:** Institutional Manager

**Is this a LIVE or TEST Filing?:** LIVE

**Is this an electronic copy of an official filing submitted in paper format?:** [ ]

### Submission Contact Information
_Not provided in this filing._

### Notification Information
**Notify via Filing Website only?:** [ ]

## N-PX: Cover Page

**Name of reporting person:** Vivo Capital, LLC

**Address:** 192 Lytton Avenue, Palo Alto, CA 94301

**Telephone number:** 650-688-0818

**Name of agent for service:** —

**Agent Address:** —, —, — —

**Reporting Period:** Report for the year ended 06/30/2025

**SEC File Number:** 028-17467

**CRD Number (if any):** —

**Other SEC File Number (if any):** —

**LEI (if any):** 25490014X9LPHXWXCC91

**Report Type (check only one):**

Institutional Manager.

- [x] Institutional Manager Voting Report

- [ ] Institutional Manager Notice Report

- [ ] Institutional Manager Combination Report

Registered Management Investment Company.

- [ ] Fund Voting Report

- [ ] Fund Notice Report

**Do you wish to provide explanatory information pursuant to Special Instruction B.4?:**

- [x] No

- [ ] Yes

**Additional information:** —

## N-PX: Summary - Included Managers

**Number of Included Institutional Managers:** 0

**Included Institutional Managers:** —

## FORM N-PX PROXY VOTING RECORD

| NAME OF ISSUER                        | CUSIP     | MEETING DATE   | VOTE DESCRIPTION                                                                                                                                                                  | VOTE CATEGORY                |     SHARES VOTED |   SHARES ON LOAN | HOW VOTED   |   SHARES VOTED FOR OR AGAINST MANAGEMENT | FOR OR AGAINST MANAGEMENT   | OTHER INFO   |
|:---|:---|:---|:---|:---|---:|---:|:---|---:|:---|:---|
| Avadel Pharmaceuticals Plc            | G29687103 | 07/30/2024     | To approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company                                                                      | SECTION 14A SAY-ON-PAY VOTES |      3.9721e+06  |                0 | FOR         |                              3.9721e+06  | FOR                         |  |
| Rezolute, Inc.                        | 76200L309 | 12/05/2024     | To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers as disclosed in the Executive Compensation section of the Proxy Statement. | SECTION 14A SAY-ON-PAY VOTES |      2.7977e+06  |                0 | FOR         |                              2.7977e+06  | FOR                         |  |
| Verona Pharma Plc                     | G9337X139 | 04/24/2025     | To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers.                                                                       | SECTION 14A SAY-ON-PAY VOTES |     21           |                0 | FOR         |                             21           | FOR                         |  |
| Verona Pharma Plc                     | 925050106 | 04/24/2025     | To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers.                                                                       | SECTION 14A SAY-ON-PAY VOTES |      1.43878e+06 |                0 | FOR         |                              1.43878e+06 | FOR                         |  |
| Celcuity Inc.                         | 15102K100 | 05/13/2025     | To approve, by a non-binding and advisory vote, compensation of the named executive officers.                                                                                     | SECTION 14A SAY-ON-PAY VOTES | 610500           |                0 | FOR         |                         610500           | FOR                         |  |
| Corbus Pharmaceuticals Holdings, Inc. | 21833P301 | 05/15/2025     | Approval, on an advisory basis, of the executive compensation of the Company's named executive officers.                                                                          | SECTION 14A SAY-ON-PAY VOTES |  75153           |                0 | FOR         |                          75153           | FOR                         |  |
| Delcath Systems, Inc.                 | 24661P807 | 05/15/2025     | To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the accompanying proxy statement ("Proxy Statement").               | SECTION 14A SAY-ON-PAY VOTES | 867164           |                0 | FOR         |                         867164           | FOR                         |  |
| Abeona Therapeutics Inc.              | 00289Y206 | 05/19/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                                     | SECTION 14A SAY-ON-PAY VOTES |      1.84275e+06 |                0 | FOR         |                              1.84275e+06 | FOR                         |  |
| Geron Corporation                     | 374163103 | 05/21/2025     | To approve, on an advisory basis, the compensation of our Named Executive Officers, as disclosed in our Proxy Statement.                                                          | SECTION 14A SAY-ON-PAY VOTES |      2.72253e+07 |                0 | FOR         |                              2.72253e+07 | FOR                         |  |
| Verastem, Inc.                        | 92337C203 | 05/22/2025     | To approve an advisory vote on the compensation of the named executive officers.                                                                                                  | SECTION 14A SAY-ON-PAY VOTES |      1.53846e+06 |                0 | FOR         |                              1.53846e+06 | FOR                         |  |
| 89bio, Inc.                           | 282559103 | 05/28/2025     | Approval of, on an advisory basis, the compensation of the Company's named executive officers.                                                                                    | SECTION 14A SAY-ON-PAY VOTES | 406804           |                0 | FOR         |                         406804           | FOR                         |  |
| Precision BioSciences, Inc.           | 74019P207 | 05/28/2025     | Approval, on an advisory (non-binding) basis, of the compensation of our named executive officers (commonly referred to as the "say-on-pay vote").                                | SECTION 14A SAY-ON-PAY VOTES |   4675           |                0 | FOR         |                           4675           | FOR                         |  |
| Precision BioSciences, Inc.           | 74019P207 | 05/28/2025     | Approval, on an advisory (non-binding) basis, of the frequency of future say-on-pay votes.                                                                                        | SECTION 14A SAY-ON-PAY VOTES |   4675           |                0 | ONE YEAR    |                           4675           | FOR                         |  |
| Dyne Therapeutics, Inc.               | 26818M108 | 05/30/2025     | To vote, on an advisory basis, to approve the compensation of our named executive officers.                                                                                       | SECTION 14A SAY-ON-PAY VOTES |      1.11496e+06 |                0 | FOR         |                              1.11496e+06 | FOR                         |  |
| Dyne Therapeutics, Inc.               | 26818M108 | 05/30/2025     | To hold an advisory vote on the frequency of future advisory votes on the compensation of our named executive officers.                                                           | SECTION 14A SAY-ON-PAY VOTES |      1.11496e+06 |                0 | ONE YEAR    |                              1.11496e+06 | FOR                         |  |
| Akero Therapeutics, Inc.              | 00973Y108 | 06/03/2025     | To consider and act upon a non-binding, advisory vote to approve the compensation of our named executive officers.                                                                | SECTION 14A SAY-ON-PAY VOTES | 201168           |                0 | FOR         |                         201168           | FOR                         |  |
| Cogent Biosciences, Inc.              | 19240Q201 | 06/04/2025     | Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.                                                                        | SECTION 14A SAY-ON-PAY VOTES |      1.12247e+06 |                0 | FOR         |                              1.12247e+06 | FOR                         |  |
| Aclaris Therapeutics, Inc.            | 00461U105 | 06/05/2025     | To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this proxy card.                             | SECTION 14A SAY-ON-PAY VOTES |      8.88889e+06 |                0 | FOR         |                              8.88889e+06 | FOR                         |  |
| Olema Pharmaceuticals, Inc.           | 68062P106 | 06/10/2025     | Approval, on an advisory basis, of the compensation of the Company's named executive officers.                                                                                    | SECTION 14A SAY-ON-PAY VOTES |      1.50586e+06 |                0 | FOR         |                              1.50586e+06 | FOR                         |  |
| Astria Therapeutics, Inc.             | 04635X102 | 06/11/2025     | The approval, by non-binding advisory vote, of our executive compensation.                                                                                                        | SECTION 14A SAY-ON-PAY VOTES |      1.55268e+06 |                0 | FOR         |                              1.55268e+06 | FOR                         |  |
| Tenax Therapeutics, Inc.              | 88032L605 | 06/11/2025     | Approval, on an advisory basis, of Tenax Therapeutics, Inc.'s 2024 named executive officer compensation.                                                                          | SECTION 14A SAY-ON-PAY VOTES | 208333           |                0 | FOR         |                         208333           | FOR                         |  |
| Tenax Therapeutics, Inc.              | 88032L605 | 06/11/2025     | Approval, on an advisory basis, on the frequency of future advisory votes on named executive officer compensation.                                                                | SECTION 14A SAY-ON-PAY VOTES | 208333           |                0 | TWO YEARS   |                         208333           | FOR                         |  |
| Trevi Therapeutics, Inc.              | 89532M101 | 06/11/2025     | Approval, on an advisory basis, of the compensation paid to our named executive officers.                                                                                         | SECTION 14A SAY-ON-PAY VOTES |      3.4879e+06  |                0 | FOR         |                              3.4879e+06  | FOR                         |  |
| Trevi Therapeutics, Inc.              | 89532M101 | 06/11/2025     | Approval, on an advisory basis, of the frequency of future advisory votes to approve the compensation paid to our named executive officers.                                       | SECTION 14A SAY-ON-PAY VOTES |      3.4879e+06  |                0 | ONE YEAR    |                              3.4879e+06  | FOR                         |  |
| COMPASS Pathways plc                  | 20451W101 | 06/12/2025     | To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers for the year ended 31 December 2024                                      | SECTION 14A SAY-ON-PAY VOTES |      1.608e+06   |                0 | FOR         |                              1.608e+06   | FOR                         |  |
| CORVUS PHARMACEUTICALS                | 221015100 | 06/12/2025     | To approve, on a non-binding advisory basis, the compensation of our named executive officers                                                                                     | SECTION 14A SAY-ON-PAY VOTES |      2.23457e+06 |                0 | FOR         |                              2.23457e+06 | FOR                         |  |
| CIDARA THERAPEUTICS, INC              | 171757206 | 06/18/2025     | Approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in the proxy statement.                                               | SECTION 14A SAY-ON-PAY VOTES | 961425           |                0 | FOR         |                         961425           | FOR                         |  |
| Cidara Therapeutics, Inc.             | 171757206 | 06/18/2025     | Approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in: the proxy statement.                                              | SECTION 14A SAY-ON-PAY VOTES | 961425           |                0 | FOR         |                         961425           | FOR                         |  |
| Viridian Therapeutics, Inc.           | 92790C104 | 06/20/2025     | To approve, on an advisory basis, the compensation of the Company's named executive officers.                                                                                     | SECTION 14A SAY-ON-PAY VOTES | 982576           |                0 | FOR         |                         982576           | FOR                         |  |
| Silence Therapeutics Plc              | 82686Q101 | 06/26/2025     | To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement.                                                          | SECTION 14A SAY-ON-PAY VOTES |      1.10545e+06 |                0 | FOR         |                              1.10545e+06 | FOR                         |  |
| Silence Therapeutics Plc              | 82686Q101 | 06/26/2025     | To indicate, on an advisory basis, the preferred frequency of shareholder advisory votes on the compensation of our named executive officers.                                     | SECTION 14A SAY-ON-PAY VOTES |      1.10545e+06 |                0 | ONE YEAR    |                              1.10545e+06 | FOR                         |  |

## N-PX: Signature Block

**Reporting Person:** Vivo Capital, LLC

**By (Signature):** Zhanping Wu

**By (Printed Signature):** Zhanping Wu

**By (Title):** Chief Compliance Officer

**Date:** 08/27/2025